{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:06:36Z","timestamp":1790355996337,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japanese Society for Radiation Oncology","award":["Japanese Society for Radiation Oncology"],"award-info":[{"award-number":["Japanese Society for Radiation Oncology"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We performed a model-based cost-effectiveness analysis of the use of surgical treatment (ST) versus chemoradiotherapy (CRT) for stage I esophageal cancer in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A model for partitioned survival analysis was developed to estimate the long-term medical costs and quality-adjusted life years (QALYs) for patients who had received either ST or CRT. Data on survival times were taken from the JCOG0502 trial. Utility values were estimated by applying a mapping algorithm based on Japanese data from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. From the perspective of public healthcare, only direct medical costs were considered. A discount rate of 2% per year was applied to long-term costs and QALYs to estimate the incremental cost-effectiveness ratio (ICER) of CRT compared to ST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incremental cost of CRT versus ST was estimated to be $26,313 (USD), the incremental QALY was 0.630, and the ICER was $41,742\/QALY. Sensitivity analysis showed that the parameter with a relatively large effect on the ICER was the utility weight of progressive disease with esophagus preserved patients in CRT. The variations in ICERs ranged from approximately $37,113\/QALY to $47,690\/QALY. With willingness-to-pay thresholds ranging from $50,000\/QALY to $100,000\/QALY, CRT was more cost-effective than ST, with the probability of being cost-effective estimated to range from 59.3% to 76.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Japan, CRT for stage I esophageal cancer may be more cost-effective than ST, if the acceptable ICER is $50,000\/QALY.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03145-5","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:44:25Z","timestamp":1784799865000},"page":"2394-2404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of chemoradiotherapy compared to surgery in patients with stage I esophageal squamous cell carcinoma in Japan"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-0137","authenticated-orcid":false,"given":"Takuro","family":"Ariga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Sakanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Katano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Japanese Society for Radiation Oncology (JASTRO) Health Insurance Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"9","key":"3145_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45(9):884\u2013891. https:\/\/doi.org\/10.1093\/jjco\/hyv088","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"3145_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda K, Hori M, Saito E et al (2021) Updated trends in cancer in Japan: incidence in 1985\u20132015 and mortality in 1958\u20132018\u2014a sign of decrease in cancer incidence. J Epidemiol 31(7):426\u2013450. https:\/\/doi.org\/10.2188\/jea.JE20200416","journal-title":"J Epidemiol"},{"issue":"1","key":"3145_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10388-022-00950-5","volume":"20","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Toh Y, Ishihara R et al (2023) Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20(1):1\u201328. https:\/\/doi.org\/10.1007\/s10388-022-00950-5","journal-title":"Esophagus"},{"key":"3145_CR4","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK (2017) Christian Wittekind. TNM classification of Malignant Tumours, 8th Edition. Wiley-Blackwell, New York","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"issue":"6","key":"3145_CR5","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1053\/j.gastro.2021.08.007","volume":"161","author":"K Kato","year":"2021","unstructured":"Kato K, Ito Y, Nozaki I et al (2021) Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology 161(6):1878\u20131886e2. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.007","journal-title":"Gastroenterology"},{"issue":"3","key":"3145_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H et al (2023) Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus 20(3):343\u2013372. https:\/\/doi.org\/10.1007\/s10388-023-00993-2","journal-title":"Esophagus"},{"issue":"3","key":"3145_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H et al (2023) Esophageal cancer practice guidelines 2022 edited by the Japan esophageal Society: part 2. Esophagus 20(3):373\u2013389. https:\/\/doi.org\/10.1007\/s10388-023-00994-1","journal-title":"Esophagus"},{"issue":"2","key":"3145_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2009.02.086","volume":"75","author":"H Ariga","year":"2009","unstructured":"Ariga H, Nemoto K, Miyazaki S et al (2009) Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 75(2):348\u2013356. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.086","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"3145_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox061","volume":"30","author":"CY Chen","year":"2017","unstructured":"Chen CY, Hsieh VCR, Chang CH et al (2017) Impacts of treatments on the quality of life among esophageal squamous cell carcinoma patients. Dis Esophagus 30(10):1\u20138. https:\/\/doi.org\/10.1093\/dote\/dox061","journal-title":"Dis Esophagus"},{"issue":"1","key":"3145_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1186\/s12885-021-09007-9","volume":"21","author":"B Sunde","year":"2021","unstructured":"Sunde B, Lindblad M, Malmstr\u00f6m M et al (2021) Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish national registry for oesophageal and gastric cancer. BMC Cancer 21(1):1277. https:\/\/doi.org\/10.1186\/s12885-021-09007-9","journal-title":"BMC Cancer"},{"issue":"3","key":"3145_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1017\/S0266462308080343","volume":"24","author":"MF Drummond","year":"2008","unstructured":"Drummond MF, Schwartz JS, J\u00f6nsson B et al (2008) Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 24(3):244\u2013258. https:\/\/doi.org\/10.1017\/S0266462308080343","journal-title":"Int J Technol Assess Health Care"},{"key":"3145_CR12","unstructured":"Japan Council for Quality Health Care Minds Clinical Practice Guideline Development Manual 2020 ver. 3.0. https:\/\/minds.jcqhc.or.jp\/methods\/cpg-development\/minds-manual\/. Accessed 18 Feb 2024"},{"issue":"1","key":"3145_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12962-022-00352-5","volume":"20","author":"R Daroudi","year":"2022","unstructured":"Daroudi R, Nahvijou A, Arab M et al (2022) A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma. Cost Eff Resour Alloc 20(1):16. https:\/\/doi.org\/10.1186\/s12962-022-00352-5","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"3145_CR14","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s11605-012-1911-9","volume":"16","author":"LG Gordon","year":"2012","unstructured":"Gordon LG, Hirst NG, Mayne GC et al (2012) Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia. J Gastrointest Surg 16(8):1451. https:\/\/doi.org\/10.1007\/s11605-012-1911-9","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"3145_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/1759-7714.12326","volume":"7","author":"CY Lin","year":"2016","unstructured":"Lin CY, Fang HY, Feng CL et al (2016) Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: a population-based matched case-control study. Thorac Cancer 7(3):288. https:\/\/doi.org\/10.1111\/1759-7714.12326","journal-title":"Thorac Cancer"},{"key":"3145_CR16","unstructured":"Guideline for Preparing Cost-effectiveness Evaluation to the Central Social Insurance Meical Council (2026) https:\/\/c2h.niph.go.jp\/tools\/guideline\/. Accessed 20 May 2026"},{"key":"3145_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. https:\/\/doi.org\/10.1186\/1471-2288-12-9","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"3145_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10388-021-00869-3","volume":"19","author":"T Nakanoko","year":"2022","unstructured":"Nakanoko T, Morita M, Nakashima Y et al (2022) Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in Japan. Esophagus 19(1):69. https:\/\/doi.org\/10.1007\/s10388-021-00869-3","journal-title":"Esophagus"},{"issue":"1","key":"3145_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12955-020-01611-w","volume":"18","author":"Y Hagiwara","year":"2020","unstructured":"Hagiwara Y, Shiroiwa T, Taira N et al (2020) Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. Health Qual Life Outcomes 18(1):354. https:\/\/doi.org\/10.1186\/s12955-020-01611-w","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"3145_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T (2021) Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health 24(8):1193\u20131202. https:\/\/doi.org\/10.1016\/j.jval.2021.03.010","journal-title":"Value Health"},{"issue":"5","key":"3145_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K et al (2022) Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 386(5):449\u2013462. https:\/\/doi.org\/10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"issue":"1","key":"3145_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/ases.12768","volume":"13","author":"M Inomata","year":"2020","unstructured":"Inomata M, Shiroshita H, Uchida H et al (2020) Current status of endoscopic surgery in Japan: the 14th national survey of endoscopic surgery by the Japan society for endoscopic surgery. Asian J Endosc Surg 13(1):7\u201318. https:\/\/doi.org\/10.1111\/ases.12768","journal-title":"Asian J Endosc Surg"},{"issue":"2","key":"3145_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00268-018-4786-4","volume":"43","author":"DE Low","year":"2019","unstructured":"Low DE, Allum W, Manzoni GD et al (2019) Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS) Society commendations. World J Surg 43(2):299\u2013330. https:\/\/doi.org\/10.1007\/s00268-018-4786-4","journal-title":"World J Surg"},{"issue":"5","key":"3145_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dote.12214","volume":"28","author":"SR Markar","year":"2015","unstructured":"Markar SR, Karthikesalingam A, Low DE (2015) Enhanced recovery pathways lead to an improvement in postoperative outcomes following esophagectomy: systematic review and pooled analysis. Dis Esophagus 28(5):468\u2013475. https:\/\/doi.org\/10.1111\/dote.12214","journal-title":"Dis Esophagus"},{"issue":"2","key":"3145_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10388-020-00718-9","volume":"17","author":"T Triantafyllou","year":"2020","unstructured":"Triantafyllou T, Olson MT, Theodorou D et al (2020) Enhanced recovery pathways vs standard care pathways in esophageal cancer surgery: systematic review and meta-analysis. Esophagus 17(2):100\u2013112. https:\/\/doi.org\/10.1007\/s10388-020-00718-9","journal-title":"Esophagus"},{"issue":"4","key":"3145_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5761\/atcs.ra.23-00064","volume":"29","author":"K Hosoda","year":"2023","unstructured":"Hosoda K, Niihara M, Harada H et al (2023) Robotic-assisted esophagectomy: current situation and future perspectives. Ann Thorac Cardiovasc Surg 29(4):168\u2013176. https:\/\/doi.org\/10.5761\/atcs.ra.23-00064","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"1","key":"3145_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12957-024-03358-w","volume":"22","author":"T Sakurai","year":"2024","unstructured":"Sakurai T, Hoshino A, Miyoshi K et al (2024) Long-term outcomes of robot-assisted versus minimally invasive esophagectomy in patients with thoracic esophageal cancer: a propensity score-matched study. World J Surg Oncol 22(1):76. https:\/\/doi.org\/10.1186\/s12957-024-03358-w","journal-title":"World J Surg Oncol"},{"key":"3145_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11701-025-02350-0","author":"C Siech","year":"2025","unstructured":"Siech C, Jannello LMI, de Angelis M et al (2025) Costs of robot-assisted vs. open approaches for 5 major cancers. J Robot Surg. https:\/\/doi.org\/10.1007\/s11701-025-02350-0","journal-title":"J Robot Surg"},{"issue":"7","key":"3145_CR29","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1245\/s10434-024-15148-5","volume":"31","author":"NM Patel","year":"2024","unstructured":"Patel NM, Patel PH, Yeung KTD et al (2024) Is robotic surgery the future for resectable esophageal cancer? A systematic literature review of oncological and clinical outcomes. Ann Surg Oncol 31(7):4420\u20134431. https:\/\/doi.org\/10.1245\/s10434-024-15148-5","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3145_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/jrr\/rraa047","volume":"61","author":"H Numasaki","year":"2020","unstructured":"Numasaki H, Teshima T, Okuda Y et al (2020) Japanese structure survey of radiation oncology in 2013. J Radiat Res 61(5):799\u2013816. https:\/\/doi.org\/10.1093\/jrr\/rraa047","journal-title":"J Radiat Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03145-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:12Z","timestamp":1790355012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03145-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3145"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03145-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8915993\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}